Name: Breaking Internal Silos to Ensure Patient Centricity is a Key Focus Company-Wide
Start: 2022-10-06T14:00:00Z
End: 2022-10-06T14:29:31.000Z
Location: BrightTALK
Rating: 5

Datateam is a modern and dynamic communications business with a comprehensive product portfolio of leading publications, websites and events across many business-to-business and healthcare sectors.

The Brighttalk Datateam webinar channel holds content from a wide variety of brands and business sectors.

Marketing surrounding online sports betting is a constantly evolving landscape.  From licensing to the review of advertising language and prohibited phrases, the U.S. has seen many different approaches to this area.  Can the industry successfully regulate itself or will regulators need to step in to police the market?  Are the recent fines levied in Ohio a sign of a changing regulatory perspective?  Will there be a ripple effect in other regulated jurisdictions where previously regulation on marketing was light-touch?  Hear from experts in the industry discuss their thoughts on the future of marketing regulation in the U.S.

Are Marketing Restrictions Coming to the U.S. Markets?

New government targets for primary school student attainment have revived the conversation on how we can use pedagogical strategies and teaching methods to improve outcomes for learners. 

A pedagogical approach is at the core of the International Baccalaureate’s Primary Years Programme (PYP), a student-centric approach to education for children aged four to 11. The inquiry-based, transdisciplinary framework builds conceptual learning and delivers excellent outcomes by providing an education that is engaging, relevant, challenging, and significant. 

Learn more at our free webinar
At 1pm (GMT) on Thursday 16 March, join Education Today and the IB to:
• Learn about pedagogy and the PYP
• Understand how the programme complements the Ofsted framework 
• Hear from school leaders sharing their experiences of how implementing the PYP has improved student outcomes.

Read more about the Primary Years Programme: https://www.ibo.org/programmes/primary-years-programme/

Speakers:

• Jane Tipple, Principal, Bearsted Primary Academy: Jane has delivered both the National Curriculum and the IB PYP in two different academies, which are both authorized IB World Schools and have received successful Ofsted inspections under the new framework. She is passionate about the aspirations, philosophy, and ethos of the IB and its values and the significant impact on learning that the programmes have on all students.

• Peter Fidczuk, Development and Recognition Manager, International Baccalaureate UK and Ireland: Peter supports schools interested in developing IB programmes, engages with UK and Irish universities to develop their understanding of the IB and is the point of contact between the IB and the English Department of Education.

How can primary schools take a pedagogical approach to improvement?

Clinical trials don’t happen in a vacuum – they are often a significant undertaking that require people to integrate new routines and procedures into their existing lives, potentially for several years. Understanding, supporting and measuring the participant experience is therefore critical to designing studies that minimise stress and burden, reduce drop-out, and create a positive feedback loop for future programmes.  

 In this webinar Langland will speak to Jonathan Moshinsky, Co-Founder and CEO of Stitch, a technology start-up supporting participant retention by enabling in-study feedback, and Sofia Fionda, Co-Founder of Boxee Group, a healthcare specialist market research agency with expertise in uncovering what motivates people to take part in trials. Join us to explore the why, how and what of improving the clinical experience for participants, sites, and sponsors.

Improving the Clinical Trial Experience: Why, How, and What?

Global clinical trials are a vital component of pharma R&D. Utilizing sites in multiple countries not only provides increased access to eligible and diverse patients - and therefore more robust data - but also promotes health equity and research and innovation across continents.

Another benefit of global clinical trials is the potential for these studies to be completed more quickly and efficiently [1]. However, around four in five clinical trials fail to meet their patient recruitment deadlines [2], which delays patient access to innovative new therapeutics and can prove costly to Sponsors.

Just as treatments are becoming more personalized, so should clinical trial patient recruitment strategies. A ‘one size fits all’ approach to enrollment fails to consider how factors such as an individual country’s culture, healthcare structure and patients’ needs can affect a site’s ability to recruit eligible participants. The key to patient enrollment success is to ‘think local’, even for global studies.

In this webinar, we will:
Discuss the benefits of using a diversified patient recruitment approach for each country within a global study
Investigate how patient recruitment strategies can differ from country to country, 
Hear from two in-country patient recruitment specialists about the challenges relevant to their regions and how they work with sites to overcome these
Share how Innovative Trials’ ‘boots-on-the-ground’ approach in more than 70 countries around the world can help accelerate patient recruitment and retention for your clinical trials.

Speakers:

Georgia Harding - Patient Recruitment Manager, Innovative Trials - georgia.hardy@innovativetrials.co.uk
Nicole Yingst - Strategist, Pfizer - Nicole.Yingst@pfizer.com
Barbara OrlosKaminska- Clinica Enrolment Manager (Poland), Innovative Trials - barbara.orloskaminska@innovativetrials.co.uk
Speaker 4: TBC

Patient Recruitment: Think Global, Act Local

To remain relevant in today’s rapidly changing, information-intense world, regulators must continually evaluate existing market conditions while considering the potential implications of external forces and advances that weigh in on how their markets operate. Featuring a distinguished panel of North American regulators who daily address complex issues like data privacy and cyber security threats to the rapidly growing digital gaming products, financial crime threats like money laundering, fraud and suspicious financial activity, and whether local or national advertising restrictions are warranted to minimize harm amid extensive player acquisition efforts, attempting to streamline the multi-jurisdictional compliance challenges that operators and suppliers face might seem a low priority but is a constant suggestion from the industry. Our panelists will begin by discussing the many challenges facing the industry as we start a new year and share their thoughts on the feasibility of building consensus toward streamlining the regulatory and licensing process.

Regulator Roundtable: regulating in a rapidly evolving world

Over the last few years, a long-running debate has been taking place about what are the appropriate approaches to assessment for today’s world and, since the conventional assessment of GCSEs and A levels was suspended during COVID-19, this debate has intensified with calls to replace GCSEs.  

Additionally, the pandemic accelerated the development of the digital classroom, and so, digital, or e-Assessments, are now on the horizon. Just what this will look like is open to question. For instance, AQA’s trial of digital GCSEs is exploring adaptive – or ‘smart’ – assessments that adjust in difficulty as students progress through the test. The International Baccalaureate (IB) has been assessing learning digitally since 2016 in its curriculum for 11 – 16 year olds, the Middle Years Programme (MYP), and has taken an alternative approach which utilises the full potential of the digital environment to assess knowledge and skills and to enhance learning in the classroom through a positive ‘backwash’ effect. 

Following the IB’s presentation at the ‘Next generation assessment – planning for the future’, (which is being held on the 17 Jan 2023  a conference sponsored by the ASCL, HMC and other organisations), we would like to invite you to learn more about the MYP and the IB’s approach to digital assessment. 

Join our free webinar at 1pm (GMT) on Thursday 26 January in partnership with the IB to learn more.

The International Baccalaureate® (IB) Middle Years Programme (MYP) is for students aged 11-16. Read more about the programme: Middle Years Programme (MYP) - International Baccalaureate® (ibo.org)

At 1pm (GMT) on Thursday 26 January, join Education Today and the IB to:
·    Learn about the MYP
·    Discover the MYP’s flexibility and its innovative digital summative assessments -  eAssessment
·    Understand how the programme complements the Ofsted framework
·    Hear two contrasting schools share their perspectives on implementing the MYP and eAssessments

Moving towards eAssessment with the Middle Years Programme (MYP)

The world is changing, and with it the skills young people need to have to succeed in their future careers, as well as understanding what is out there for them. A panel of experts will discuss how best to prepare them for their futures, and what platforms and tools are out there to help them do so.

Preparing Young People for the Future with Real-World Skills

Though equipment manufacturers provide ratings for equipment such as heat exchangers, it is an unfortunate fact that actual performance can vary massively. This is undoubtedly worrying for consultants, contractors and end-users, with the former lacking a verifiable basis for product selection, and the latter potentially subject to additional field testing and component performance margins. 

Similarly, contractors cannot hold full confidence that specified equipment will deliver to performance levels set out in proposals. But beyond these differing operational concerns, all stakeholders are united by a common concern – the financial impact of critical equipment not performing as it should, especially when energy costs are rising.

In this CPD-certified webinar session, Gemma Reeves, Business Unit Manager; Energy at Alfa Laval, demonstrates the importance of third-party independent performance verification to making sure your heat exchangers are working as efficiently as possible.

With over 20 years’ experience in heat transfer, Gemma will be providing advice and insight on the impact of the AHRI Certification Program in guaranteeing consistent heat exchanger performance and peace-of-mind when selecting such critical components. She will explore the performance criteria behind the accreditation, its importance to consultants, contractors and end-users, and how it can save you money in the long (or short) term.

Certified Heat Exchangers: The key to efficient systems. CIBSE-approved session

With the cost of everything on the rise, how can schools best adapt and continue to innovate how they teach - without spending money? EVERFI and a panel of experts will discuss the wealth of no-cost EdTech available, and how it can be best used to support teachers and students, including EVERFI’s offering in this sphere.

Innovation doesn’t have to be expensive: free EdTech resources for your school

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new and effective treatments. 

We know patient recruitment can be challenging even for non-complex trials, but this issue is exacerbated for rare disease studies due to the much smaller patient populations involved. This can lead to lengthy delays in bringing what can be cutting-edge and potentially life-changing therapies to market.

With the global rare disease market expected to be worth more than US$547 billion within the next 10 years overcoming these challenges is critical. This webinar will:
explore some of the patient recruitment challenges in rare disease studies, particularly relating to sickle cell trials
hear from a patient and family member about what it means to live with a rare disease and highlight strategies to accelerate patient recruitment for these specialized trials. 

Learning Objective
Patient recruitment challenges in rare disease studies
Challenges in sickle cells studies
Family/Patient perspective 
Accelerating patient recruitment in rare disease studies

Speaker 1 - Whitney Taynton - Business Unit Head, Site Enrollment Optimization, Innovative Trials
Speaker 2 - Donna Dail - Director, Patient Recruitment Programs (Rare Disease)
Speaker 3 - Margaret Alege - Patient

Overcoming Patient Recruitment Challenges in Rare Disease Trials

Value-based contracts (VBC) are increasingly considered by companies for many types of therapies, with some suggesting that VBC will become the default for them across their portfolio. This webinar will explore the sustainability of this approach, what payers and national HTA bodies really want from negotiations and the future of innovative contracting. 

Speakers:

Josie Godfrey: Former Associate Director for Highly Specialised Technologies, NICE 
Josie’s market access experience covers the establishment of NICE’s Highly Specialised Technologies and Advisory Group for National Specialised Services programmes, including a process for agreeing Managed Access Agreements for very rare diseases. Josie leads Duchenne UK’s Project HERCULES and co-chairs EUCOPE’s CGT Working Group.

Malcolm Qualie: Former Medicines Lead for Specialised Services, NHS England 
Malcolm recently retired from his role as NHS England’s Medicines Lead for Specialised Services, where he worked with companies on commercial agreements and service development. Malcolm has been a member of the National Pharmaceutical Supply Group, the national HIV HRG reference group, and the NICE Commissioner reference panel for NICE Guidelines.

Heather McDonald: Global VP, Market Access – Cell and Gene Therapies + Digital Health, Bayer Pharmaceuticals
Heather’s team works with healthcare systems worldwide to ensure that patients have access to Bayer’s innovative products.  Heather’s mandate includes Market Access Strategy, Pricing, HEOR and Public Affairs.  Previously, Heather was the Vice President of Market Access and Government Affairs for Bayer Canada.

Agreeing sustainable value-based contracts with payers: myths and realities

COVID-19 has had a huge impact on how we all think and act. Our working environments may look very different now to the way they did pre-pandemic, and not all the changes have been negative. More flexible work schedules and an acceptance of new ways of thinking have allowed the diversity, equity and inclusion (DE&I) space to take a big step forward. But this is not the full story; some employees feel more isolated and excluded now than ever before.

In this panel debate, speakers will offer an introduction to DE&I in the workplace pre-and post-pandemic, plus a close look at the challenges, opportunities and limitations COVID-19 has created.

Talking points:

• What does ‘diversity’ mean to you and what does/should DE&I look like in the pharma industry?
• How has COVID-19 changed the way we approach DE&I in the workplace?
• Are we doing better in certain sectors of the industry than others?
• Has hybrid working helped or hindered a diverse working environment? Is it less inclusive?
• What is the benefit to the industry if DE&I is delivered successfully? How has COVID-19 furthered this goal?
• How can we inspire the next generation? How can we encourage them into the pharma industry and ultimately push for leadership roles?

Speakers:

Andrés López Castaño, Vaccine Therapeutic Area Lead, Global LGBTQI+ ERG Lead, MSD Switzerland
Tricia Lucas-Clarke, Early Talent Recruitment Inclusion and Diversity Manager, GSK
Noor Shaker, Senior Vice President and General Manager, X-Chem
Sandra Van de Cauter, Innovation Enabling Partner and Diversity and Inclusion Lead, F. Hoffmann-La Roche 
MODERATOR: Marsha N. Ganthier, President, HBA Paris Chapter

Diversity in Pharma: The Impact of COVID-19 on DE&I

Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to market. But recruitment is also one of the biggest challenges for trials. More than four in five studies fail to meet their recruitment deadlines, which can result in costly delays for sponsors and puts sites under increasing pressure. 

This issue has been exacerbated by the COVID-19 pandemic; with many trials initially put on hold and now restarting, sponsors want to make up for lost time by accelerating patient recruitment and retention. However, clinical trial staff are struggling to clear this enrollment backlog.

This webinar will explore some of the key challenges to patient recruitment particularly since COVID-19, and highlight how a 'boots on the ground' approach via Clinical Enrollment Managers (CEMs) can help supercharge patient recruitment and retention strategy by:
understanding the local environment and culture in each country where sites are based
working with sites and developing strategies to help them overcome recruitment barriers
sustained community engagement within key patient populations, including those who are traditionally underrepresented in trials

Learning Objective
- COVID19 and Patient Recruitment Challenges
- Accelerating patient recruitment with local CEMs
- Benefits of deploying a boots-on-the-ground approach

Who Should attend
Pharma, Clinical Research Organisations (CROs) and Biotech senior leadership
Clinical Trial/Clinical Study Leads
Clinical Operations Specialists
Clinical Operations Directors/VPs
Therapeutic Strategy Leads

Accelerating patient recruitment in clinical trials post COVID-19

"Smarter strategies: How to deliver precise, customer-centric digital engagement within the new NHS landscape" 

Having traditionally found itself near the bottom of digital adoption league tables, the scale and maturity of customer engagement practices within the pharmaceutical industry, accelerated by the COVID-19 pandemic, are now building at considerable pace. 

Investment in digital continues to rise year-on-year, while customer expectations follow a similar trajectory, with healthcare professionals (HCPs) saying they now want to continue taking a significant proportion of pharma rep calls. A growing consensus is forming around hybrid engagement models as the preferred model for the new NHS landscape.

Yet taking successful and effective steps to improving engagement requires a precise, personalised, view of the customer. Wilmington Healthcare’s Simon Grime, Tina White and Julian Snape take a practical look at how to use a 360-degree view of the customer to support a highly personalised engagement strategy. Bringing together NHS insider and Industry insight, the panel will explore:

•        What's changing across the NHS and how is that affecting the data requirements for understanding the customer?
•        What are the components of an effective digital engagement approach?
•        How do you effectively measure ROI and impact? 
•        What are the challenges Industry needs to address to make this happen?
•        What are the implications for structure and commercial optimisation?

Speakers:
Simon Grime: Digital Engagement Director, Wilmington Healthcare
Tina White: Principal Clinical Consultant – Commissioning, Wilmington Healthcare
Julian Snape: Commercial Optimisation Director, Wilmington Healthcare

Smarter strategies: precise customer-centric digital engagement with the NHS

Gas distribution systems are critical to the effective operation of many industrial facilities around the world. Despite the importance of these systems, however, opportunities to improve their performance and cost-effectiveness are often missed or misunderstood. Increasing changeover pressure may seem like a good way to improve system flow, for example, but it often does so at the expense of bottled gas. Adding regulators may help you control supply pressure, but it also adds cost to your system. So, how do you know what the ideal gas distribution setup is for you?
Attend this webinar to:
•        Gain a basic understanding of the fluid dynamics that affect pressure control in gas distribution systems, learning to interpret flow curves and recognize phenomena like lockup, droop, and supply pressure effect (SPE)
•        Learn how inlet pressure affects regulator performance and when to specify certain regulator types and configurations to effectively control gas system pressures
•        Understand the inherent trade-offs between gas utilization and flow capacity and how to select both the right changeover pressure and automatic changeover panel design for your operations

Optimizing Gas Distribution: Accounting for Changeovers, Regulators, and More

Prepare your pupils for their trip to KidZania London with this preliminary session with PDSA. 

This session provides an overview of what pets need to be healthy and happy. Based on the care of dogs, cats and rabbits, it teaches the audience how to be responsible pet owners.

When visiting KidZania London, pupils can then put this learning in to practise in the pet wellbeing centre!

KidZania London and PDSA present Get PetWise

We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient recruitment.

Between 2008 and 2018, fewer than two in three (63%) of the 230 clinical trials that led to cancer drug approvals by the Food and Drug Administration (FDA) in the US, recorded participants’ ethnicity. This lack of diversity is a major issue: studies show that different groups can respond to treatments in various ways, resulting in some medicines being prescribed differently.

This session will highlight some of the factors underpinning the lack of patient diversity in clinical trials, investigate the implications this has for patients, and discuss what we can do in practice to improve diversity in clinical trials.

Speakers
Kate Shaw - Founder/CEO - Innovative Trials
Sandra Amro - Global Clinical Trial Diversity Team Lead- Pfizer
Jane Thurston - Senior Patient Recruitment Lead - Parexel

Learning Objective
What are the factors behind the lack of representations in clinical trials?
What are the consequences of the lack of diversity in Clinical Trials?
How do we improve diversity in clinical trials in practice?

Diversity in Clinical Trials : A more inclusive approach in patient recruitment

Mark and Urs will be discussing the pros and cons of an enterprise-wide approach to patient centricity, and explore the measurable benefits it could deliver.

• Who should be involved in patient centric initiatives? 
• Should organisations focus their energies (and budget) on customer-facing or medical colleagues – or is there a benefit to including other functions? 
• Will an all-encompassing approach benefit the people, the organisation, the patients? 
• Is this the approach that will help companies meet their patient centricity goals – or is it an unnecessary extravagance?

Breaking Internal Silos to Ensure Patient Centricity is a Key Focus Company-Wide

Patient Centric

Patient Centricity

Pharmaceutical

Patient Engagement

Healthcare

The building and construction community brings together building and construction management professionals. Find relevant webinars and videos on building materials, building construction, renovations and more presented by recognized thought leaders. Join the conversation by participating in live webinars and round table discussions on building and construction trends.

Building and Construction

The research and development community on BrightTALK brings together leading professionals in healthcare, technology and manufacturing to present on current topics in their fields. From big data in healthcare to online forensics training and medical research practices, the community is an exceptional resource for those looking to expand their knowledge. Be part of the conversation by joining the community and participating in interactive live webinars.

Breaking Internal Silos to Ensure Patient Centricity is a Key Focus Company-Wide

Presented by

About this talk

More from this channel